Structure Therapeutics (NASDAQ:GPCR) Hits New 52-Week Low – Time to Sell?

Structure Therapeutics Inc. (NASDAQ:GPCR) shares reached a new 52-week low during mid-day trading on Friday . The company traded as low as $25.74 and last traded at $25.80, with a volume of 324671 shares changing hands. The stock had previously closed at $27.04.

Wall Street Analyst Weigh In

GPCR has been the topic of a number of research analyst reports. Cantor Fitzgerald restated an “overweight” rating and issued a $65.00 target price on shares of Structure Therapeutics in a research note on Monday, September 23rd. JMP Securities reaffirmed a “market outperform” rating and set a $91.00 target price on shares of Structure Therapeutics in a research report on Wednesday, December 18th. HC Wainwright reiterated a “buy” rating and issued a $80.00 target price on shares of Structure Therapeutics in a report on Thursday, December 19th. Morgan Stanley assumed coverage on Structure Therapeutics in a research note on Monday, September 23rd. They set an “overweight” rating and a $118.00 price target on the stock. Finally, Stifel Nicolaus initiated coverage on shares of Structure Therapeutics in a research note on Wednesday. They issued a “buy” rating and a $50.00 price objective for the company. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $81.29.

Structure Therapeutics Price Performance

The stock has a fifty day moving average of $32.03 and a 200 day moving average of $36.48. The stock has a market cap of $1.45 billion, a price-to-earnings ratio of -34.13 and a beta of -2.78.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of GPCR. GAMMA Investing LLC raised its stake in shares of Structure Therapeutics by 4,155.6% during the 4th quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock worth $31,000 after buying an additional 1,122 shares during the period. Sandia Investment Management LP purchased a new position in Structure Therapeutics during the second quarter valued at $39,000. Assetmark Inc. grew its position in shares of Structure Therapeutics by 120.0% in the third quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock valued at $58,000 after purchasing an additional 719 shares during the period. Quarry LP purchased a new stake in shares of Structure Therapeutics during the second quarter worth about $79,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of Structure Therapeutics by 60.1% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company’s stock worth $158,000 after purchasing an additional 1,420 shares during the last quarter. 91.78% of the stock is owned by institutional investors and hedge funds.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.